Interview with Darren Ji, CEO, PharmaLegacy
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Address: Building 7, 388 Jialilue Rd.,Zhangjiang High-Tech Park, Shanghai,China
Tel: (86) 21-6100 2280
Web: http://www.pharmalegacy.com/Home.aspx?lang=en
PharmaLegacy Laboratories is a leading preclinical Contract Research Organization (CRO) providing specialty pharmacology services in Bone Metabolism, Immune Diseases, Inflammation, Oncology, and Orthopaedics and Tissue Engineering. The core competency of PharmaLegacy stems from our pioneering work and expertise in developing and running specialized animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall we provide one-stop shopping of preclinical pharmacology services for early proof of concept of therapeutics and fulfillment of regulatory requirement.
Aspiring to collaborate with our global clients to accelerate their missions to develop new therapies, PharmaLegacy provides quality services with faster turnaround and higher productivity of R&D to IND/IDE endeavors for pharmaceutical, biotech, and orthopaedic device companies around the world.
The PharmaLegacy management team consists of world-renowned scholars, top service scientists and seasoned business leaders from the US and Shanghai. We have fully established animal pharmacology models of rodents, rabbits, dogs, sheep, goats and non-human primates which are used to serve our current clients of large multinational pharmaceutical and medical device companies, as well as small- to-medium-sized biotech companies.
Research
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Following China’s vaccine scandal earlier this year, the country’s drug administration has considerably tightened up inspection processes of vaccine manufacturers which is causing shortages and raising the risk of widespread…
China’s stupendous economic resurgence over the past four decades never ceases to awe, but what has captured attention in recent years has been the country’s international awakening. Against a nasty…
Cash has always ruled the start-up world and when it comes to the healthcare and life sciences sphere, the heavy investment required for R&D and the long timelines make it even…
The Greater Bay Area’s – and in particular, Shenzhen’s – prowess in life sciences manufacturing and development must also be attributed to the decades of experience and expertise gained from…
The Honorable William Zarit, Chairman of the American Chamber of Commerce in Beijing (AmCham Beijing), shares the insights gained over his 25 years in China, the key priorities of AmCham…
Eric Bouteiller, formerly with Ipsen (most recently as SVP Asia PC Operations based in Beijing) and chairman of the R&D-based Pharmaceutical Association Committee (RDPAC) till December 2017, speaks in his…
In 2013, Chinese President Xi Jinping launched the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative, corralling the two Special Administrative Regions (SARs) of Hong Kong and Macao with Guangdong, one…
Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry. Napoleon once said: “China is a sleeping giant. Let her sleep, for…
Chinese ecommerce behemoths Alibaba and JD.com are being used to buy and sell tens of thousands of prescription medicines, skirting regulations in what is a legal grey area. According to…
Andy A. Liu, CEO of CW Data Technologies, a joint venture between WuXi AppTec and China Electronics Data Corporation at the intersection of Big Data and healthcare, discusses emerging trends…
Simon Yam, managing director of Geodis Greater China, shares the importance of the Greater China region to Geodis globally, the region’s strong performance and growth, the strategic importance of the…
Gene Shigekawa, managing partner of MAZ World, shares their recent move to the Hong Kong Science and Technology Park (HKSTP) in 2017, the revolutionary ostrich-derived antibody they hope to further…
See our Cookie Privacy Policy Here